INSM catalyst calendar

INSMED Inc

Upcoming catalysts
9
Cash runway
15.6 months
Cash & investments
$1160M
Phase 3 programs
11

INSMED Inc is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on November 5, 2026, a projected date rather than a confirmed one. There are 9 upcoming events on record.

Cash runway is approximately 15.6 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 40 concluded trials, 90% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
November 5, 2026 est. Next quarterly earnings (projected) Earnings —
November 25, 2026 A Study to Assess the Potential CYP3A Induction Effect of Brensocatib on the Pharmacokinetics (PK) of Midazolam in Healthy Participants Trial Milestone Phase 1
December 31, 2026 An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH) Trial Milestone Phase 2/Phase 3
February 7, 2027 A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Normal Hepatic Function and Participants With Hepatic Impairment Trial Milestone Phase 1
March 22, 2027 A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of INS1033 in Healthy Participants Trial Milestone Phase 1
December 28, 2028 A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH) Trial Milestone Phase 3
December 30, 2028 Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) Trial Milestone Phase 3
August 31, 2030 A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Progressive Pulmonary Fibrosis (PPF) Trial Milestone Phase 3
January 22, 2031 An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) Trial Milestone Phase 3

Track INSM alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open INSM in the tracker

Recent history

DateEventTypePhase
October 5, 2026 8-K filed: Leadership change, Reg FD disclosure Corporate —
August 6, 2026 Quarterly results filed (8-K) Earnings —
July 16, 2026 8-K filed: Reg FD disclosure Filing —
May 7, 2026 Quarterly results filed (8-K) Earnings —
April 7, 2026 8-K filed: Reg FD disclosure, Other event Filing —
April 1, 2026 An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) Trial Milestone Phase 2/Phase 3
March 23, 2026 8-K filed: Reg FD disclosure, Other event Filing —
February 19, 2026 Quarterly results filed (8-K) Earnings —
February 12, 2026 A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS) Trial Milestone Phase 2
January 9, 2026 8-K filed: Reg FD disclosure Filing —
December 17, 2025 8-K filed: Reg FD disclosure, Other event Filing —
November 21, 2025 Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex Trial Milestone Phase 3
November 18, 2025 8-K filed: Reg FD disclosure, Other event Filing —
October 30, 2025 Quarterly results filed (8-K) Earnings —
October 25, 2025 A Study to Assess the Relative Bioavailability After a Single Inhalation Administration of Treprostinil Palmitil Inhalation Powder (TPIP) Formulation 2 (F2) to TPIP Formulation 3 (F3) in Healthy Participants Trial Milestone Phase 1
September 30, 2025 A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Trial Milestone Phase 2
August 12, 2025 8-K filed: Reg FD disclosure, Other event Filing —
August 7, 2025 Quarterly results filed (8-K) Earnings —
June 13, 2025 8-K filed: Reg FD disclosure, Other event Filing —
June 10, 2025 8-K filed: Reg FD disclosure, Other event Filing —
June 6, 2025 8-K filed: Other event Filing —
May 16, 2025 8-K filed: Leadership change Corporate —
May 8, 2025 Quarterly results filed (8-K) Earnings —
April 24, 2025 8-K filed: Other event Filing —
April 24, 2025 8-K/A filed: Other event Filing —
April 17, 2025 8-K filed: Leadership change Corporate —
March 27, 2025 A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension Trial Milestone Phase 2
October 28, 2024 A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis Trial Milestone Phase 3
September 3, 2024 Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe AD (Atopic Dermatitis) Trial Milestone Phase 2
May 24, 2024 A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy Participants Trial Milestone Phase 1

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.